PBMC derived from heterozygous C1858T PTPN22 T1D patients were treated with different doses of lipoplexes (80 and 100 pmols of siRNA) for 48 and 72 h of incubation. This evidence concerns the gene PTPN22 and type 1 diabetes mellitus.